crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 706386

Zbornik radova

Autori: Babić, Mirjana; Vogrinc, Željka; Dejanović, Nenad; Borovečki, Fran; Hof, Patrick R.; Šimić, Goran
Naslov: Improved early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid biomarkers
Izvornik: 9th FENS Forum of Neuroscience / FENS (ur.). - Milano : FENS , 2014. 100-100.
Dio CC časopisa: NE
Skup: 9th FENS Forum of Neuroscience
Mjesto i datum: Milano, Italija, 05-09.07.2014.
Ključne riječi: Mild cognitive impairment; Alzheimer's disease; cerebrospinal fluid biomarkers
Sažetak:
Alzheimer's disease (AD) is the leading primary cause of dementia. Mild cognitive impairment (MCI) is a syndrome characterized by cognitive impairment without dementia. About 12% of MCI patients however have an initial stage of AD. There is an urgent need for novel CSF biomarkers to improve the early diagnosis of AD. Visinin-like protein-1 (VILIP-1), a neuron- specific intracellular calcium sensor protein, is a novel promising biomarker of AD. VILIP-1 was previously identified as a marker of neuronal injury. Thus, the objective of this study was to assess whether combination of cerebrospinal fluid VILIP-1 and tau protein phosphorylated at threonine 181 (p-tau 181) could improve early diagnosis of AD. The concentration of VILIP-1 and p-tau 181 was determined using ELISA kits in the CSF of 60 patients with probable AD, 30 MCI patients, and 14 healthy controls (HC). Levels of VILIP-1 were significantly higher in the group of AD patients than in MCI patients (p = 0.001). ROC curve analysis showed that VILIP-1 could differentiate AD patients from HC with a sensitivity and specificity of 86.7% and 57.1%, respectively, while VILIP-1/p-tau 181 ratio reached 75% sensitivity and 71.4% specificity. About 50% of MCI patients had VILIP-1 and p-tau 181 levels higher than the cut-off (assessed by ROC curve analysis). Even though a follow-up period of at minimum 5 years is necessary to determine whether MCI high-risk patients will convert to AD, the combination of VILIP-1 and p-tau 181 could considerably improve AD detection in the preclinical stages of the disease.
Vrsta sudjelovanja: Poster
Vrsta prezentacije u zborniku: Sažetak
Vrsta recenzije: Međunarodna recenzija
Projekt / tema: HRZZ-09/16, 108-1081870-1942
Izvorni jezik: ENG
Kategorija: Znanstveni
Znanstvena područja:
Temeljne medicinske znanosti,Kliničke medicinske znanosti,Psihologija
Tiskani medij: da
Upisao u CROSBI: Goran Šimić (gsimic@hiim.hr), 23. Srp. 2014. u 16:04 sati



Verzija za printanje   za tiskati


upomoc
foot_4